Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285629 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Efficacy of Klotho and Follistatin Gene Therapy
A Early Phase 1 study of Healthy Adults, sponsored by Minicircle.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT07285629: Recruiting Early Phase 1 study of Healthy Adults, sponsored by Minicircle.
NCT07285629 is a Early Phase 1 study of Healthy Adults that is actively recruiting participants, run by Minicircle. The registered enrollment target is 30 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285629, a Early Phase 1 study of Healthy Adults, is actively recruiting participants, sponsored by Minicircle.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
Primary Outcome
Serum α-Klotho protein concentration will be quantified using a validated ELISA. Results will be determined from picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.
Conditions Studied
Interventions
- GENETIC Follistatin and klotho gene therapy
Study Locations (2)
Texas
- Apeiron Center - Austin
Bay Islands
- Global Alliance of Regenerative Medicine (GARM) Clinic - Roatán
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What NCT07285629 shows while recruiting
NCT07285629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 1 intervention - of which Follistatin and klotho gene therapy is the first listed.
NCT07285629 reports a single indexed study location in Texas, Bay Islands.
Frequently Asked Questions
What is clinical trial NCT07285629 about?
NCT07285629 is a clinical study titled "Safety and Efficacy of Klotho and Follistatin Gene Therapy". The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
What is the current status of trial NCT07285629?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-16. Estimated completion is 2026-06.
What conditions does trial NCT07285629 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT07285629?
The interventions under investigation include: Follistatin and klotho gene therapy (GENETIC).
Who is sponsoring clinical trial NCT07285629?
This trial is sponsored by Minicircle, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285629 being conducted?
This trial has 2 study locations across Texas, Bay Islands. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07285629's enrollment target sits among peer trials
30 21st of 33 higher than 11 of 33 other Healthy Adults trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude
RECRUITING · NA
-
Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines
RECRUITING · NA
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Health Properties of Pecan Nut Consumption
RECRUITING · NA
-
The Brain Processes Underlying Speech Motor Learning and Speech Production
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI